ArticleEJNMMI research2022
Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET.
Article in EJNMMI research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Emerging frontiers and challenges of artificial intelligence in PSMA-PET imaging: pioneering a new chapter in prostate cancer care.Japanese journal of radiology · 2026Review
- A computer-aided diagnosis tool in prostate cancer patients with biochemical recurrence using 18F-PSMA PET/CT imaging.Medical physics · 2026Article
- Standardizing PSMA PET/CT reporting in prostate cancer: from structured frameworks to AI-assisted interpretation.Abdominal radiology (New York) · 2026Review
- Evaluating indeterminate bone lesions and lymph nodes on PSMA-PET: a multidisciplinary consensus algorithm and 1-year implementation results.European radiology · 2026Article
- Non-invasive diagnosis strategy integrating PSMA PET/CT and mpMRI for patients with suspected prostate cancer: a multi-center study.BMC medicine · 2026Article
- Integrating Multiparametric MRI and PSMA PET Imaging in Prostate Cancer: Toward a Unified Diagnostic and Risk-Stratification Paradigm.Medicina (Kaunas, Lithuania) · 2026Review
- Artificial intelligence in the early diagnosis of prostate cancer: from multimodal imaging to liquid biopsy.Frontiers in oncology · 2026Review
- Application value of radiomics features based on PSMA PET/CT in diagnosis of clinically significant prostate cancer: a comparison between manual and automatic segmentation.BMC medical imaging · 2025Article
- The potential of generative AI with prostate-specific membrane antigen (PSMA) PET/CT: challenges and future directions.Medical review (2021) · 2025Review
- Meeting Upcoming Clinical and Diagnostic Needs in Oncologic Imaging: A Structured Reporting System for Fibroblast-Activation-Protein-Targeted Imaging-FAP-RADS Version 1.0.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Review
- Current Status and Future Perspectives of Nuclear Medicine in Prostate Cancer from Imaging to Therapy: A Comprehensive Review.Biomedicines · 2025Review
- Comparison of Prostate-specific Membrane Antigen Reporting and Data System Version 1.0 versus 2.0 for Prostate Cancer Assessment.Radiology. Imaging cancer · 2025Article
- Review
- Catalyzing Precision Medicine: Artificial Intelligence Advancements in Prostate Cancer Diagnosis and Management.Cancers · 2024Review
- Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- The Application of Radiomics and AI to Molecular Imaging for Prostate Cancer.Journal of personalized medicine · 2024Review
- Improving Generalizability of PET DL Algorithms: List-Mode Reconstructions Improve DOTATATE PET Hepatic Lesion Detection Performance.Bioengineering (Basel, Switzerland) · 2024Article
- Structured reporting in prostate cancer: the revolution of quality in nuclear medicine scan interpretation.European radiology · 2024Article
- A Systematic Review on Artificial Intelligence Evaluating Metastatic Prostatic Cancer and Lymph Nodes on PSMA PET Scans.Cancers · 2024Review
- Prostate-specific Membrane Antigen Reporting and Data System Version 2.0.European urology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundAccurate classification of sites of interest on prostate-specific membrane antigen (PSMA) positron emission tomography (PET) images is an important diagnostic requirement for the differentiation of prostate cancer (PCa) from foci of physiologic uptake. We developed a deep learning and radiomics framework to perform lesion-level and patient-level classification on PSMA PET images of patients with PCa.
methodsThis was an IRB-approved, HIPAA-compliant, retrospective study. Lesions on [
resultsPSMA PET scans from 267 men with PCa had 3794 lesions assigned to PSMA-RADS categories. The framework yielded AUROC values of 0.87 and 0.90 for lesion-level and patient-level PSMA-RADS classification, respectively, on the test set. The framework yielded AUROC values of 0.92 and 0.85 for lesion-level and patient-level PCa classification, respectively, on the test set. A t-SNE analysis revealed learned relationships between the PSMA-RADS categories and disease findings. Mean confidence scores reflected the expected accuracy and were significantly higher for correct predictions than for incorrect predictions (P < 0.05). Measured probability scores reflected the likelihood of PCa consistent with the PSMA-RADS framework.
conclusionThe framework provided lesion-level and patient-level PSMA-RADS and PCa classification on PSMA PET images. The framework was interpretable and provided confidence and probability scores that may assist physicians in making more informed clinical decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.